文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

对一例重症成年Wiskott-Aldrich综合征患者实施基因治疗

Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult.
PubMed 文献 · Blood · 2017-07-17

本文报告一例30岁重症Wiskott-Aldrich综合征(WAS)患者,表现为皮肤血管炎、炎性关节病、间歇性多克隆淋巴增殖及慢性肾病,需长期免疫抑制治疗。经减低强度预处理后,输注自体慢病毒载体(LV-w1.6 WASp)基因修饰造血干细胞,观察到快速植入及多克隆转基因阳性功能性T细胞扩增,髓系和B细胞谱系转基因标记持续至20个月。患者停用免疫抑制及外源免疫球蛋白,血管炎病变及促炎标志物改善。作者认为,对重症慢性并发症且异基因移植风险不可接受的成年WAS患者,自体慢病毒载体基因治疗是可行策略。

要点

  • 30岁重症WAS患者接受自体慢病毒载体基因治疗后,多克隆转基因阳性T细胞快速扩增并持续植入。
  • 髓系和B细胞谱系转基因标记持续至20个月观察期,患者停用免疫抑制及外源免疫球蛋白。
  • 血管炎病变及促炎标志物改善,作者认为该策略对异基因移植风险不可接受的成年重症WAS患者可行。

核心结论

  • 对重症慢性并发症且异基因移植风险不可接受的成年WAS患者,自体慢病毒载体基因治疗是可行策略。

研究设计与样本

  • 本文为病例报告,描述一例30岁重症WAS患者接受自体慢病毒载体(LV-w1.6 WASp)基因治疗,经减低强度预处理后输注基因修饰造血干细胞。
  • 该试验在www.clinicaltrials.gov注册,注册号为NCT01347242。

主要发现

  • 患者为30岁已行脾切除的WAS患者,表现为皮肤血管炎、炎性关节病、间歇性多克隆淋巴增殖及显著慢性肾病,需长期免疫抑制治疗。
  • 经减低强度预处理后,观察到快速植入及多克隆转基因阳性功能性T细胞扩增,髓系和B细胞谱系转基因标记持续至20个月观察期。
  • 患者停用免疫抑制及外源免疫球蛋白支持,血管炎病变及促炎标志物改善。

临床怎么用

  • 作者认为,自体慢病毒载体基因治疗是成年重症WAS伴慢性并发症且异基因移植风险不可接受患者的可行策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Until recently, hematopoietic stem cell transplantation was the only curative option for Wiskott-Aldrich syndrome (WAS). The first attempts at gene therapy for WAS using a ϒ-retroviral vector improved immunological parameters substantially but were complicated by acute leukemia as a result of insertional mutagenesis in a high proportion of patients. More recently, treatment of children with a state-of-the-art self-inactivating lentiviral vector (LV-w1.6 WASp) has resulted in significant clinical benefit without inducing selection of clones harboring integrations near oncogenes. Here, we describe a case of a presplenectomized 30-year-old patient with severe WAS manifesting as cutaneous vasculitis, inflammatory arthropathy, intermittent polyclonal lymphoproliferation, and significant chronic kidney disease and requiring long-term immunosuppressive treatment. Following reduced-intensity conditioning, there was rapid engraftment and expansion of a polyclonal pool of transgene-positive functional T cells and sustained gene marking in myeloid and B-cell lineages up to 20 months of observation. The patient was able to discontinue immunosuppression and exogenous immunoglobulin support, with improvement in vasculitic disease and proinflammatory markers. Autologous gene therapy using a lentiviral vector is a viable strategy for adult WAS patients with severe chronic disease complications and for whom an allogeneic procedure could present an unacceptable risk. This trial was registered at www.clinicaltrials.gov as #NCT01347242.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Morris EC, Fox T, Chakraverty R, et al. Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. Blood. 2017. PMID: 28716862. doi:10.1182/blood-2017-04-777136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。